Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10174320 | 0.86 | USP30 (0.57) | USP30HRH3L3MBTL1RETDGAT1 | |
| SCHEMBL32678039 | 0.85 | USP30 (0.56) | USP30L3MBTL1RETDGAT1GAA | |
| SCHEMBL32678038 | 0.85 | USP30 (0.56) | USP30L3MBTL1RETDGAT1GAA | |
| SCHEMBL16648632 | 0.84 | KMT2A (0.58) | USP30L3MBTL1RETDGAT1KMT2A | |
| SCHEMBL27404757 | 0.84 | USP30 (0.55) | USP30RETDGAT1KMT2APOLB | |
| SCHEMBL326931 | 0.84 | L3MBTL1 (0.58) | USP30HRH3L3MBTL1RETDGAT1 | |
| SCHEMBL595334 | 0.84 | SHMT2 (0.59) | USP30L3MBTL1RETDGAT1KMT2A | |
| SCHEMBL16648856 | 0.84 | L3MBTL1 (0.57) | USP30L3MBTL1RETKMT2AMAPT | |
| SCHEMBL30890320 | 0.84 | USP30 (0.55) | USP30RETDGAT1KMT2APOLB | |
| SCHEMBL374689 | 0.84 | USP30 (0.55) | USP30L3MBTL1RETDGAT1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590963-B1 | (3-METHYLPYRROLIDIN-3-YL)METHYL PYRIDINYL ETHER DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-12-03 | — | — | EP | disclosed |
| US-8507535-B2 | Methyl-pyrrolidine ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2590963-A1 | (3 -METHYLPYRROLIDIN- 3 - YL) METHYL PYRIDINYL ETHER DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004207-A1 | (3 -METHYLPYRROLIDIN- 3 - YL) METHYL PYRIDINYL ETHER DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010212-A1 | METHYL-PYRROLIDINE ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010212-A1 | METHYL-PYRROLIDINE ETHER DERIVATIVES | OPRM1, OPRK1, OPRD1 | USP30 4373/4885HRH3 1070/4885L3MBTL1 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.